This page lists our patient-driven research studies into ROS1+ cancers. ROS1+ cancer is a rare cancer, occurring in a small percentage of lung, gastric, and ovarian cancers, as well as in melanoma, glioblastoma, cholangiocarcinoma, angiosarcoma, and melanoma. The number of patients available for study at any one cancer center are limited. As ROS1 patients, we can accelerate research in ways no one else can. Through social media and online patient communities, ROS1 patients are helping researchers discover risk factors for ROS1 cancer, the biology of ROS1 cancer, and hopefully new treatments for our disease.
Open to all patients with ROS1+ solid tumors.
Patients who have a medically-necessary procedure (surgery, biopsy, or draining of pleural fluid) send excess specimens to University of Colorado to make cell lines that researchers can use to study ROS1+ cancer.
Goal: understand what drives tumor formation, therapeutic response, and acquired therapeutic resistance in ROS1 cancer
Cell Line Initiative Principal Investigator: Robert C. Doebele, MD, PhD, University of Colorado
Results: see data on our ROS1 Cancer Model Project page
To Participate: Contact The ROS1ders at ros1cancer.patient @gmail.com
Short Polls across the ROS1der Cohort
The ROS1ders conduct short, informal polls among ROS1+ patients using Survey Monkey, and share the de-identified results on this website in hopes of accelerating research in and treatments for ROS1+ cancers.
Goal: determine how many ROS1der patients might be available to participate in research, and whether they are willing to participate in research
Start date: November 2016
Close date: ongoing
Results: posted at http://wp.me/P6JQMq-iH and updated periodically
To Participate: go to this webpage https://www.surveymonkey.com/r/N8S5P5K